Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 8 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| EMISPHERE TECHNOLOGIES INC | 50,000 | reported | 15 May 2009 | tx 2+75,000 |
| Atea Pharmaceuticals, Inc. | 29,600 | reported | 20 Jun 2025 | tx 27+1,285,811−1,248,628 |
| VAXGEN INC | 17,500 | reported | 09 Jun 2008 | tx 4+82,500 |
| PROTEOSTASIS THERAPEUTICS, INC. | 17,400 | reported | 29 Jun 2020 | tx 13+463,585−777,604 |
| Atreca, Inc. | 12,000 | reported | 13 Jun 2023 | tx 8+123,315−75,315 |
| Forte Biosciences, Inc. | 7,500 | reported | 04 Oct 2019 | tx 5+80,081 |
| Lineage Cell Therapeutics, Inc. | 500 | reported | 20 Aug 2013 | tx 2+20,500 |
| ESSA Pharma Inc. | 0 | reported | 09 Oct 2025 | tx 26+304,437−1,099,451 |
| Rain Therapeutics Inc. | 0 | reported | 26 Jan 2024 | tx 17+1,084,207−1,852,602 |
| Kezar Life Sciences, Inc. | 0 | reported | 11 May 2026 | tx 33+1,049,309−646,440 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 11 May 2026 | TENDER | Kezar Life Sciences, Inc. | 89,069 | — | |
| 11 May 2026 | OTHER | Kezar Life Sciences, Inc. | 3,500 | 0.00 USD | deriv |
| 11 May 2026 | OTHER | Kezar Life Sciences, Inc. | 5,000 | 0.00 USD | deriv |
| 11 May 2026 | OTHER | Kezar Life Sciences, Inc. | 5,000 | 0.00 USD | deriv |
| 11 May 2026 | OTHER | Kezar Life Sciences, Inc. | 2,600 | 0.00 USD | deriv |
| 11 May 2026 | OTHER | Kezar Life Sciences, Inc. | 2,600 | 0.00 USD | deriv |
| 09 Oct 2025 | OTHER | ESSA Pharma Inc. | 784,404 | — | |
| 20 Jun 2025 | EXERCISE | Atea Pharmaceuticals, Inc. | 29,600 | 0.00 USD | |
| 20 Jun 2025 | EXERCISE | Atea Pharmaceuticals, Inc. | 29,600 | 0.00 USD | deriv |
| 20 Jun 2025 | GRANT_AWARD | Atea Pharmaceuticals, Inc. | 41,200 | 0.00 USD | deriv |
| 20 Jun 2025 | GRANT_AWARD | Atea Pharmaceuticals, Inc. | 29,600 | 0.00 USD | deriv |
| 18 Jun 2025 | GRANT_AWARD | Kezar Life Sciences, Inc. | 5,000 | 0.00 USD | deriv |
| 15 Jan 2025 | PURCHASE | Atea Pharmaceuticals, Inc. | 15,000 | 3.19 USD | |
| 16 Jan 2025 | PURCHASE | Atea Pharmaceuticals, Inc. | 10,000 | 3.36 USD | |
| 10 Dec 2024 | SALE | Atea Pharmaceuticals, Inc. | 359,606 | 2.85 USD | anomaly |
| 21 Jun 2024 | GRANT_AWARD | Atea Pharmaceuticals, Inc. | 29,600 | 0.00 USD | deriv |
| 21 Jun 2024 | GRANT_AWARD | Atea Pharmaceuticals, Inc. | 41,200 | 0.00 USD | deriv |
| 20 Jun 2024 | GRANT_AWARD | Kezar Life Sciences, Inc. | 50,000 | 0.00 USD | deriv |
| 16 Jun 2024 | EXERCISE | Atea Pharmaceuticals, Inc. | 33,150 | 0.00 USD | |
| 16 Jun 2024 | EXERCISE | Atea Pharmaceuticals, Inc. | 33,150 | 0.00 USD | deriv |
| 25 Mar 2024 | GRANT_AWARD | ESSA Pharma Inc. | 50,000 | 0.00 USD | deriv |
| 26 Jan 2024 | TENDER | Rain Therapeutics Inc. | 1,005,207 | — | |
| 26 Jan 2024 | OTHER | Rain Therapeutics Inc. | 20,000 | — | deriv |
| 26 Jan 2024 | OTHER | Rain Therapeutics Inc. | 24,000 | — | deriv |
| 26 Jan 2024 | OTHER | Rain Therapeutics Inc. | 35,000 | — | deriv |
4 purchases reported after at least 12 months of silence — most recent on 04 Feb 2020.